Background Patient preference studies can inform decision-making across all stages of the
medical product life cycle (MPLC). The treatment landscape for advanced prostate cancer …

Background: Radium-223 is approved for treatment of bone metastases in metastatic
castration-resistant prostate cancer (mCRPC). After the ALSYMPCA trial showed overall …

Background Treatment options for patients with metastatic hormone-sensitive prostate
cancer (mHSPC) have broadened, and treatment decisions can have a long-lasting impact …

Background The potential cardiovascular adverse events associated with new-generation
androgen receptor pathway inhibitors (ARPI) in the treatment of prostate cancer remain …

Aims There are no direct comparisons of the relative cost-effectiveness of second-
generation anti-androgens (enzalutamide and apalutamide) used in managing metastatic …

Background Upfront chemotherapy prolongs overall survival for men with metastatic,
hormone-sensitive prostate cancer (mHSPC) based on data from clinical trials. We sought to …

Background Extraprostatic extension (EPE) of prostate cancer is associated with a poor
prognosis. The broad-based capsule-tumor interface has been recognized as one of the …

Background: Abiraterone acetate (AA) is a selective inhibitor of CYP17 α-hydroxylase, which
is crucial for androgen biosynthesis. Apigenin (Api) is a natural plant-derived flavonoid with …

Despite advances in treatment of lethal prostate cancer, the incidence of prostate cancer
brain metastases is increasing. In this sense, we analyzed the molecular profile, as well as …

Metastatic hormone-sensitive prostate cancer (mHSPC) is usually categorized as high-or
low-volume disease. This is relevant because low-and high-volume metastatic disease are …